3rd Rare & Genetic Kidney Disease Drug Development Summit 2023

Accelerating the Development of Therapeutic Treatments for IgAN, FSGS, Alport Syndrome, PKD & More!

80+ experts joined from the FDA, EMA, Eloxx Pharmaceuticals, HI-Bio, Chinook Therapeutics, Novo Nordisk, Janssen, Travere Therapeutics, Otsuka, Sanofi and many more to:

  • Leverage genetic, transcriptomic, and proteomic profiling to identify future indications
  • Incorporate real-world evidence into trial planning to reduce the barriers to clinical trial diversity
  • Better understand patients’ experiences to ameliorate clinical trial design
  • Navigate endpoints beyond total kidney volume and eGFR slope during earlier phases of drug development for efficient assessment of clinical signal

2023 World-Class Speaker Faculty Included:

Previously Attending Companies Include:

MicrosoftTeams-image (15)

Our 2023 Partners:

medibeacon logo
Natera_Logo_Transparent Background




 "Very informative session, with expert speakers who are thought leaders in drug development in rare & genetic kidney disease"



vertext logo


 "Powerful, key players in one room to move the field forward"


vifor logo


"A good opportunity for scientists, drug developers and patient advocates to meet and discuss current issues in rare kidney diseases"


sanofi new


"The breadth across both preclinical and clinical hot topics was excellent, as was the quality of the speakers' presentations and the chairpersons' moderation"




"The coverage of preclinical discoveries blended with updates on drug development clinical trials was very enjoyable"


Other Events in the Series: